| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Gillman A | |
| P2860 | cites work | Spatial, temporal, and species variation in prevalence of influenza A viruses in wild migratory birds | Q21089625 |
| Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus | Q21144425 | ||
| Systematic review of influenza resistance to the neuraminidase inhibitors | Q21261835 | ||
| Evolution and ecology of influenza A viruses | Q24634698 | ||
| Update on avian influenza A (H5N1) virus infection in humans | Q28264923 | ||
| Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance | Q28282405 | ||
| Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. | Q28369317 | ||
| Detection of the antiviral drug oseltamivir in aquatic environments | Q28475674 | ||
| Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards | Q28477046 | ||
| Compliance to oseltamivir among two populations in Oxfordshire, United Kingdom affected by influenza A(H1N1)pdm09, November 2009--a waste water epidemiology study | Q28486193 | ||
| Resistance mutation R292K is induced in influenza A(H6N2) virus by exposure of infected mallards to low levels of oseltamivir | Q28535274 | ||
| Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses | Q28541953 | ||
| Intra- and inter-pandemic variations of antiviral, antibiotics and decongestants in wastewater treatment plants and receiving rivers | Q28543255 | ||
| Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan | Q28545776 | ||
| Oseltamivir Resistance in Influenza A(H6N2) Caused by an R292K Substitution in Neuraminidase Is Not Maintained in Mallards without Drug Pressure | Q28548682 | ||
| Oseltamivir resistance during treatment of influenza A (H5N1) infection | Q29618722 | ||
| Influenza virus in a natural host, the mallard: experimental infection data | Q30000979 | ||
| Fate of three anti-influenza drugs during ozonation of wastewater effluents - degradation and formation of transformation products | Q30197017 | ||
| Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water. | Q30203367 | ||
| Oseltamivir-resistant influenza A (H1N1) virus strain with an H274Y mutation in neuraminidase persists without drug pressure in infected mallards | Q30205021 | ||
| Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance | Q30222909 | ||
| Stockpiling antiviral drugs for the next influenza pandemic | Q30227621 | ||
| Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir | Q30306773 | ||
| Global epidemiology of influenza: past and present. | Q30326723 | ||
| Influenza A viruses of migrating wild aquatic birds in North America. | Q30349928 | ||
| Assessing exposure risks for aquatic organisms posed by Tamiflu use under seasonal influenza and pandemic conditions. | Q30354171 | ||
| The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. | Q30356303 | ||
| Potential risks associated with the proposed widespread use of Tamiflu. | Q30360496 | ||
| Continuing challenges in influenza. | Q30363190 | ||
| The environmental fate of the antiviral drug oseltamivir carboxylate in different waters. | Q30371155 | ||
| Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan | Q30371865 | ||
| Environmental fate of the antiviral drug Tamiflu in two aquatic ecosystems. | Q30374221 | ||
| The pandemic potential of avian influenza A(H7N9) virus: a review. | Q30377088 | ||
| An environmental risk assessment for oseltamivir (Tamiflu) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions. | Q30378462 | ||
| Diversity of influenza viruses in swine and the emergence of a novel human pandemic influenza A (H1N1). | Q30380872 | ||
| Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan | Q30384168 | ||
| Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets | Q30389462 | ||
| Perspectives on influenza evolution and the role of research | Q30390922 | ||
| Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype | Q30391856 | ||
| Occurrence and fate of oseltamivir carboxylate (Tamiflu) and amantadine in sewage treatment plants. | Q30392424 | ||
| Pandemic pharmaceutical dosing effects on wastewater treatment: no adaptation of activated sludge bacteria to degrade the antiviral drug oseltamivir (Tamiflu®) and loss of nutrient removal performance | Q30397023 | ||
| Photofate of oseltamivir (Tamiflu) and oseltamivir carboxylate under natural and simulated solar irradiation: kinetics, identification of the transformation products, and environmental occurrence | Q30401896 | ||
| Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience | Q30409023 | ||
| Environmental release of oseltamivir from a Norwegian sewage treatment plant during the 2009 influenza A (H1N1) pandemic | Q30410100 | ||
| Removal of the antiviral agent oseltamivir and its biological activity by oxidative processes | Q30411512 | ||
| Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. | Q30412554 | ||
| The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host | Q30418377 | ||
| Influenza virus resistance to neuraminidase inhibitors. | Q30428660 | ||
| Influenza A virus evolution and spatio-temporal dynamics in Eurasian wild birds: a phylogenetic and phylogeographical study of whole-genome sequence data | Q30938686 | ||
| The evolutionary genetics and emergence of avian influenza viruses in wild birds | Q33339404 | ||
| Hitchhiking and the population genetic structure of avian influenza virus | Q33680452 | ||
| Global patterns of influenza a virus in wild birds | Q33995214 | ||
| Permissive secondary mutations enable the evolution of influenza oseltamivir resistance | Q34118992 | ||
| Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010 | Q34129986 | ||
| Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses | Q34339407 | ||
| Investigating avian influenza infection hotspots in old-world shorebirds. | Q34430711 | ||
| Avian influenza virus exhibits rapid evolutionary dynamics | Q34562380 | ||
| Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient | Q34597785 | ||
| Global transmission of oseltamivir-resistant influenza | Q34955928 | ||
| Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in Sweden | Q35099847 | ||
| Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir | Q35823104 | ||
| Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. | Q35882160 | ||
| Mutations of neuraminidase implicated in neuraminidase inhibitors resistance | Q37022596 | ||
| Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015. | Q37710503 | ||
| Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors | Q39577999 | ||
| Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in Mallard ducks | Q40004651 | ||
| Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. | Q40045076 | ||
| Mass balance of anti-influenza drugs discharged into the Yodo River system, Japan, under an influenza outbreak | Q40125722 | ||
| The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities | Q42250194 | ||
| Synchronous dynamics of observed and predicted values of anti-influenza drugs in environmental waters during a seasonal influenza outbreak. | Q42288589 | ||
| Reassessing the risks of Tamiflu use during a pandemic to the Lower Colorado River | Q42754886 | ||
| Maximizing the value of drug stockpiles for pandemic influenza | Q42789427 | ||
| Emergence of a Multidrug-Resistant Pandemic Influenza A (H1N1) Virus | Q42873717 | ||
| Removal of oseltamivir (Tamiflu) and other selected pharmaceuticals from wastewater using a granular bioplastic formulation entrapping propagules of Phanerochaete chrysosporium | Q42950923 | ||
| Dissipation and removal of oseltamivir (Tamiflu) in different aquatic environments | Q43131214 | ||
| Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. | Q43174669 | ||
| Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relevance? | Q43182004 | ||
| Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). | Q44805348 | ||
| Resistant influenza A viruses in children treated with oseltamivir: descriptive study | Q45036693 | ||
| Migration strategy affects avian influenza dynamics in mallards (Anas platyrhynchos). | Q45238279 | ||
| Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. | Q45369153 | ||
| High prevalence of influenza A virus in ducks caught during spring migration through Sweden | Q45414962 | ||
| Coincident ruddy turnstone migration and horseshoe crab spawning creates an ecological 'hot spot' for influenza viruses. | Q51175013 | ||
| Long-term variation in influenza A virus prevalence and subtype diversity in migratory mallards in northern Europe. | Q51466413 | ||
| Effects of influenza A virus infection on migrating mallard ducks. | Q51671413 | ||
| Photodegradation of pharmaceuticals in the aquatic environment: A review | Q56623661 | ||
| Community Transmission of Oseltamivir-Resistant A(H1N1)pdm09 Influenza | Q57077387 | ||
| Influenza glycoproteins: Hemagglutinin and neuraminidase | Q57884070 | ||
| Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012 | Q95438587 | ||
| P433 | issue | 0 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | avian influenza | Q43987 |
| oseltamivir | Q211509 | ||
| P304 | page(s) | 32870 | |
| P577 | publication date | 2016-10-11 | |
| P1433 | published in | Infection ecology & epidemiology | Q27724378 |
| P1476 | title | Risk of resistant avian influenza A virus in wild waterfowl as a result of environmental release of oseltamivir | |
| P478 | volume | 6 |
| Q54978166 | Anti-influenza effect and action mechanisms of the chemical constituent gallocatechin-7-gallate from Pithecellobium clypearia Benth. |
| Q47548869 | Environmental resistance development to influenza antivirals: a case exemplifying the need for a multidisciplinary One Health approach including physicians. |
Search more.